Olema Pharmaceuticals, Inc. reports clinical, corporate, and financing developments as a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other cancers. Olema Oncology updates commonly center on palazestrant (OP-1250), an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, and OP-3136, an orally available KAT6 inhibitor.
Recurring company news covers clinical and preclinical presentations at oncology meetings, endocrine-driven cancer biology, ER+/HER2- breast cancer studies, combination approaches with endocrine therapy and CDK inhibitors, operating results, public offerings, inducement equity grants, and board or management changes.
Olema Oncology (Nasdaq: OLMA) announced a proposed public offering of common stock and, for some investors, pre-funded warrants, subject to market and other conditions.
The offering is to be made from a shelf registration on Form S-3 declared effective January 15, 2025. Olema expects to grant underwriters a 30-day option to buy up to an additional 15% of the total shares and shares underlying the pre-funded warrants. TD Cowen is acting as book-running manager. No assurance exists regarding timing, size, or terms; a preliminary prospectus supplement will be filed with the SEC and made available on SEC.gov.
Olema Oncology (NASDAQ: OLMA) reported third-quarter 2025 results and clinical progress on Nov 10, 2025. Key developments include a clinical trial collaboration with Pfizer to evaluate palazestrant plus atirmociclib, initiation of the OPERA-02 Phase 3 trial of palazestrant with ribociclib in frontline ER+/HER2- metastatic breast cancer, and presented updated Phase 1b/2 palazestrant+ribociclib data at ESMO 2025.
Financials: $329.0M in cash, cash equivalents, and marketable securities as of Sept 30, 2025; GAAP net loss of $42.2M for Q3 2025 versus $34.6M year-ago. GAAP R&D was $40.0M for the quarter. Company expects OPERA-01 topline in H2 2026 and to initiate the palazestrant+atirmociclib study in Q4 2025.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to five new employees to purchase an aggregate of 148,600 shares, effective November 3, 2025. The awards were approved by the Compensation Committee under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options vest over four years (25% after one year, then monthly for 36 months), have a 10-year term, and an exercise price of $8.42 per share, equal to the last reported sale price on Nasdaq on November 3, 2025.
Olema Oncology (Nasdaq: OLMA) will participate in three investor conferences in November 2025: a Guggenheim fireside chat on Nov 10, 2025 at 10:30 a.m. ET in Boston; a UBS presentation on Nov 12, 2025 at 8:00 a.m. ET in Palm Beach; and a Jefferies London fireside chat on Nov 19, 2025 at 9:00 a.m. GMT / 4:00 a.m. ET in London.
Live webcasts and recordings will be available, as permitted by event hosts, in the Events and Presentations section of Olema’s investor relations site at ir.olema.com.
Olema Oncology (Nasdaq: OLMA) will present a trial-in-progress poster for the Phase 3 OPERA-02 study at the 2025 San Antonio Breast Cancer Symposium (SABCS 2025) on December 12, 2025.
The randomized, double-blind, active-controlled trial compares palazestrant plus ribociclib versus letrozole plus ribociclib as first-line therapy for ER+, HER2- advanced or metastatic breast cancer. Poster: Abstract 264, Presentation PS5-12-18, 12:30pm–2:00pm CT. A poster copy will be posted on Olema's publications page per SABCS embargo policy.
Olema Oncology (Nasdaq: OLMA) reported updated Phase 1b/2 data for palazestrant plus ribociclib in ER+/HER2- advanced or metastatic breast cancer presented at ESMO 2025 on October 20, 2025.
Key clinical readouts: in the 120 mg palazestrant cohort (n=56, median follow-up >19 months) median PFS was 15.5 months overall; among patients with prior CDK4/6 inhibitor therapy median PFS was 12.2 months (9.2 months for ESR1 wild-type; 13.8 months for ESR1 mutant). Across 72 patients, the combination showed favorable tolerability, no new safety signals, and no drug-drug interactions. Data support the ongoing Phase 3 OPERA-02 trial in the frontline setting.
Olema Oncology (Nasdaq: OLMA) granted stock options to three new employees for an aggregate of 77,000 shares, effective October 1, 2025, approved under the company's 2022 Inducement Plan as required by Nasdaq Listing Rule 5635(c)(4).
The options vest over four years (25% after one year, then 36 equal monthly installments), have a 10-year term, and an exercise price of $11.04 per share (equal to the last reported sale price on Nasdaq on October 1, 2025). Olema disclosed the awards to comply with Nasdaq rules governing inducement grants.
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has granted stock options to four new employees under its 2022 Inducement Plan. The grants total 124,000 shares with an exercise price of $6.47 per share.
The stock options feature a 4-year vesting schedule with 25% vesting after the first year and the remaining portion vesting monthly over three years. The options have a 10-year term and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA) has announced a new clinical trial collaboration with Pfizer (NYSE: PFE) to evaluate the combination of palazestrant and atirmociclib in patients with ER+/HER2- metastatic breast cancer.
The Phase 1b/2 study will assess the safety and combinability of Olema's palazestrant with Pfizer's investigational CDK4 inhibitor atirmociclib in approximately 35 patients, with trial initiation expected in H2 2025. Results will inform a potential pivotal Phase 3 trial in frontline metastatic breast cancer.
Under the agreement, Pfizer will supply atirmociclib while Olema leads the study. Both companies will jointly own clinical data and inventions, with Olema retaining full global commercial rights to palazestrant.
Olema Oncology (NASDAQ:OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in five major investor conferences in September 2025.
The company will present at Citi's Biopharma Back to School Conference (Sept 2), Wells Fargo Healthcare Conference (Sept 3), Cantor Global Healthcare Conference (Sept 4), Morgan Stanley Global Healthcare Conference (Sept 8), and H.C. Wainwright Global Investment Conference (Sept 9). All conferences will take place in Boston and New York, featuring a mix of presentations and fireside chats.
Investors can access live webcasts and recordings through Olema's investor relations website at ir.olema.com.